For research use only. Not for therapeutic Use.
Loxiglumide(CAT: M012588) is a potent, orally active, and selective CCK-A receptor antagonist which stimulates calorie intake and hunger feelings in humans. Loxiglumide inhibits pancreatic secretion of digestive enzymes, and also blocks CCK-induced gastric secretions and emptying. Intravenous administration of loxiglumide antagonized the CCK-induced reduction of gastric emptying in rats, acceleration of intestinal transport in mice, increase in ileal motility in rabbits, gallbladder contraction in guinea pigs and acceleration of gallbladder emptying in mice.
| CAS Number | 107097-80-3 |
| Molecular Formula | C21H30Cl2N2O5 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Storage | -20°C |
| IUPAC Name | 4-[(3,4-dichlorobenzoyl)amino]-5-[3-methoxypropyl(pentyl)amino]-5-oxopentanoic acid |
| InChI | InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27) |
| InChIKey | QNQZBKQEIFTHFZ-UHFFFAOYSA-N |
| SMILES | CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl |
| Reference | </br>1:The effects on diet, anastomotic type, and loxiglumide on gastric emptying following gastrojejunostomy. Yucel T, Gonullu D, Orhan Gurer A, Duzman R, Nihat Koksoy F, Yilmaz N, Sit M.Int J Surg. 2009 Apr;7(2):163-7. doi: 10.1016/j.ijsu.2009.01.010. Epub 2009 Feb 13. PMID: 19342323 Free Article</br>2:Effects of the cholecystokinin A receptor antagonist loxiglumide on the proliferation and cell cycle time of pancreatic acinar cells in rats. Kanemitsu D, Sakagami J, Motoyoshi T, Nakajima T, Kataoka K.Pancreas. 2006 Mar;32(2):190-6. PMID: 16552340 </br>3:Loxiglumide Rotta research. Katschinski M.IDrugs. 2002 May;5(5):469-74. PMID: 15570466 </br>4:Use of a hepta-Tyr antibiotic modified silica stationary phase for the enantiomeric resolution of D,L-loxiglumide by electrochromatography and nano-liquid chromatography. Fanali S, D/’Orazio G, Quaglia MG, Rocco A.J Chromatogr A. 2004 Oct 8;1051(1-2):247-52. PMID: 15532580 </br>5:Effect of cholecystokinin1 receptor antagonist loxiglumide (CR1505) on basal pancreatic exocrine secretion in conscious rats. Ishizaki K, Kinbara S, Kawamura M, Kimura K, Shiratori K, Takeuchi T.Pancreas. 2003 Jan;26(1):87-91. PMID: 12499923 </br>6:Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan. Shiratori K, Takeuchi T, Satake K, Matsuno S; Study Group of Loxiglumide in Japan..Pancreas. 2002 Jul;25(1):e1-5. PMID: 12131781 </br>7:Inhibitory effect of loxiglumide (CR 1505), a cholecystokinin receptor antagonist, on N-nitrosobis(2-oxopropyl) amine-induced biliary carcinogenesis in Syrian hamsters. Ogura Y, Matsuda S, Itho M, Sasaki H, Tanigawa K, Shimomura M.World J Surg. 2002 Mar;26(3):359-65. Epub 2002 Jan 18. PMID: 11865375 </br>8:Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Beglinger C, Degen L, Matzinger D, D/’Amato M, Drewe J.Am J Physiol Regul Integr Comp Physiol. 2001 Apr;280(4):R1149-54. PMID: 11247838 Free Article</br>9:Clinical evaluation of cholecystokinin-A- receptor antagonist (loxiglumide) for the treatment of acute pancreatitis. A preliminary clinical trial. Study Group of Loxiglumide in Japan. Ochi K, Harada H, Satake K.Digestion. 1999;60 Suppl 1:81-5. PMID: 10026438 </br>10:Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models. Satake K, Kimura K, Saito T.Digestion. 1999;60 Suppl 1:64-8. PMID: 10026435 |
